384 related articles for article (PubMed ID: 20616071)
1. Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant.
Li X; Fujio M; Imamura M; Wu D; Vasan S; Wong CH; Ho DD; Tsuji M
Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13010-5. PubMed ID: 20616071
[TBL] [Abstract][Full Text] [Related]
2. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
[TBL] [Abstract][Full Text] [Related]
3. Colocalization of a CD1d-Binding Glycolipid with a Radiation-Attenuated Sporozoite Vaccine in Lymph Node-Resident Dendritic Cells for a Robust Adjuvant Effect.
Li X; Kawamura A; Andrews CD; Miller JL; Wu D; Tsao T; Zhang M; Oren D; Padte NN; Porcelli SA; Wong CH; Kappe SH; Ho DD; Tsuji M
J Immunol; 2015 Sep; 195(6):2710-21. PubMed ID: 26254338
[TBL] [Abstract][Full Text] [Related]
4. Co-localization of a CD1d-binding glycolipid with an adenovirus-based malaria vaccine for a potent adjuvant effect.
Li X; Huang J; Kawamura A; Funakoshi R; Porcelli SA; Tsuji M
Vaccine; 2017 May; 35(24):3171-3177. PubMed ID: 28483194
[TBL] [Abstract][Full Text] [Related]
5. Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant.
Padte NN; Li X; Tsuji M; Vasan S
Clin Immunol; 2011 Aug; 140(2):142-51. PubMed ID: 21185784
[TBL] [Abstract][Full Text] [Related]
6. Tailored design of NKT-stimulatory glycolipids for polarization of immune responses.
Hung JT; Huang JR; Yu AL
J Biomed Sci; 2017 Mar; 24(1):22. PubMed ID: 28335781
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of C-5″ and C-6″-modified α-GalCer analogues as iNKT-cell agonists.
Guillaume J; Pauwels N; Aspeslagh S; Zajonc DM; Elewaut D; Van Calenbergh S
Bioorg Med Chem; 2015 Jul; 23(13):3175-82. PubMed ID: 26003341
[TBL] [Abstract][Full Text] [Related]
8. Identification of C-glycoside analogues that display a potent biological activity against murine and human invariant natural killer T cells.
Li X; Chen G; Garcia-Navarro R; Franck RW; Tsuji M
Immunology; 2009 Jun; 127(2):216-225. PubMed ID: 19489127
[TBL] [Abstract][Full Text] [Related]
9. Phage display-derived recombinant antibodies with TCR-like specificity against alpha-galactosylceramide and its analogues in complex with human CD1d molecules.
Denkberg G; Stronge VS; Zahavi E; Pittoni P; Oren R; Shepherd D; Salio M; McCarthy C; Illarionov PA; van der Merwe A; Besra GS; Dellabona P; Casorati G; Cerundolo V; Reiter Y
Eur J Immunol; 2008 Mar; 38(3):829-40. PubMed ID: 18253930
[TBL] [Abstract][Full Text] [Related]
10. A potent adjuvant effect of a CD1d-binding NKT cell ligand in human immune system mice.
Li X; Huang J; Kaneko I; Zhang M; Iwanaga S; Yuda M; Tsuji M
Expert Rev Vaccines; 2017 Jan; 16(1):73-80. PubMed ID: 27801602
[TBL] [Abstract][Full Text] [Related]
11. Invariant TCR rather than CD1d shapes the preferential activities of C-glycoside analogues against human versus murine invariant NKT cells.
Li X; Shiratsuchi T; Chen G; Dellabona P; Casorati G; Franck RW; Tsuji M
J Immunol; 2009 Oct; 183(7):4415-21. PubMed ID: 19734232
[TBL] [Abstract][Full Text] [Related]
12. Structural evaluation of potent NKT cell agonists: implications for design of novel stimulatory ligands.
Schiefner A; Fujio M; Wu D; Wong CH; Wilson IA
J Mol Biol; 2009 Nov; 394(1):71-82. PubMed ID: 19732779
[TBL] [Abstract][Full Text] [Related]
13. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.
Hermans IF; Silk JD; Gileadi U; Salio M; Mathew B; Ritter G; Schmidt R; Harris AL; Old L; Cerundolo V
J Immunol; 2003 Nov; 171(10):5140-7. PubMed ID: 14607913
[TBL] [Abstract][Full Text] [Related]
14. Structure-Function Implications of the Ability of Monoclonal Antibodies Against α-Galactosylceramide-CD1d Complex to Recognize β-Mannosylceramide Presentation by CD1d.
Clark K; Yau J; Bloom A; Wang J; Venzon DJ; Suzuki M; Pasquet L; Compton BJ; Cardell SL; Porcelli SA; Painter GF; Zajonc DM; Berzofsky JA; Terabe M
Front Immunol; 2019; 10():2355. PubMed ID: 31649670
[TBL] [Abstract][Full Text] [Related]
15. Avidity of CD1d-ligand-receptor ternary complex contributes to T-helper 1 (Th1) polarization and anticancer efficacy.
Wu TN; Lin KH; Chang YJ; Huang JR; Cheng JY; Yu AL; Wong CH
Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17275-80. PubMed ID: 21987790
[TBL] [Abstract][Full Text] [Related]
16. Invariant NKT cells facilitate cytotoxic T-cell activation via direct recognition of CD1d on T cells.
Qin Y; Oh S; Lim S; Shin JH; Yoon MS; Park SH
Exp Mol Med; 2019 Oct; 51(10):1-9. PubMed ID: 31653827
[TBL] [Abstract][Full Text] [Related]
17. Photoactivable Glycolipid Antigens Generate Stable Conjugates with CD1d for Invariant Natural Killer T Cell Activation.
Veerapen N; Kharkwal SS; Jervis P; Bhowruth V; Besra AK; North SJ; Haslam SM; Dell A; Hobrath J; Quaid PJ; Moynihan PJ; Cox LR; Kharkwal H; Zauderer M; Besra GS; Porcelli SA
Bioconjug Chem; 2018 Sep; 29(9):3161-3173. PubMed ID: 30085659
[TBL] [Abstract][Full Text] [Related]
18. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
Wu L; Gabriel CL; Parekh VV; Van Kaer L
Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798
[TBL] [Abstract][Full Text] [Related]
19. Species-specific activity of glycolipid ligands for invariant NKT cells.
Dangerfield EM; Cheng JM; Knight DA; Weinkove R; Dunbar PR; Hermans IF; Timmer MS; Stocker BL
Chembiochem; 2012 Jun; 13(9):1349-56. PubMed ID: 22639457
[TBL] [Abstract][Full Text] [Related]
20. Glycolipid activators of invariant NKT cells as vaccine adjuvants.
Kharkwal SS; Arora P; Porcelli SA
Immunogenetics; 2016 Aug; 68(8):597-610. PubMed ID: 27377623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
